Table 4:
Parameter | Unadjusted Relative Cost Ratios RCR (95% CI) |
Multivariable-adjusted Relative Cost Ratiosa RCR (95% CI) |
---|---|---|
Total Costs in 12 months post-dx | ||
OAA Use (ref. none) | 1.40 (1.31-1.49) | 1.36 (1.28-1.45) |
Race (ref. White Non-Hispanic) | ||
Black Non-Hispanic | 0.86 (0.76-0.97) | 1.00 (0.88-1.14) |
Hispanic | 1.08 (0.98-1.20) | 1.19 (1.06-1.33) |
Other | 0.99 (0.88-1.12) | 1.04 (0.92-1.18) |
Cancer-specific Costs in 12 months post-dx | ||
OAA Use (ref. none) | 1.48 (1.35-1.62) | 1.47 (1.34-1.61) |
Race (ref. White Non-Hispanic) | ||
Black Non-Hispanic | 0.68 (0.57-0.81) | 0.92 (0.76-1.11) |
Hispanic | 1.01 (0.88-1.17) | 1.20 (1.01-1.41) |
Other | 0.96 (0.80-1.14) | 1.02 (0.85-1.22) |
Inpatient Admission Costs in 12 months post-dx | ||
OAA Use (ref. none) | 1.13 (1.06-1.22) | 1.08 (1.01-1.16) |
Race (ref. White Non-Hispanic) | ||
Black Non-Hispanic | 1.06 (0.93-1.20) | 1.07 (0.93-1.23) |
Hispanic | 1.25 (1.13-1.40) | 1.09 (0.97-1.23) |
Other | 1.25 (1.09-1.42) | 1.08 (0.94-1.24) |
Multivariable models additionally adjusted for patient age, sex, cancer stage at initial diagnosis, tumor histology, region of residence, residence in metropolitan area, year of metastatic diagnosis, Medicaid dual enrollment status, zip code characteristics, patient comorbidities, and patient’s prior year total Medicare spending